0001209191-18-041303.txt : 20180703
0001209191-18-041303.hdr.sgml : 20180703
20180703182253
ACCESSION NUMBER: 0001209191-18-041303
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180701
FILED AS OF DATE: 20180703
DATE AS OF CHANGE: 20180703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mulroy Michael H.
CENTRAL INDEX KEY: 0001509725
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12830
FILM NUMBER: 18938861
MAIL ADDRESS:
STREET 1: 1300 N. KELLOGG DRIVE, SUITE D
CITY: ANAHEIM
STATE: CA
ZIP: 92807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOTIME INC
CENTRAL INDEX KEY: 0000876343
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 943127919
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1010 ATLANTIC AVENUE
STREET 2: SUITE 102
CITY: ALAMEDA
STATE: CA
ZIP: 94501
BUSINESS PHONE: 5105213390
MAIL ADDRESS:
STREET 1: 1010 ATLANTIC AVENUE
STREET 2: SUITE 102
CITY: ALAMEDA
STATE: CA
ZIP: 94501
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-07-01
0
0000876343
BIOTIME INC
BTX
0001509725
Mulroy Michael H.
1010 ATLANTIC AVENUE
SUITE 102
ALAMEDA
CA
94501
1
0
0
0
Common Shares, no par value
32550
D
Option to Purchase Common Shares
2.06
2018-07-01
4
A
0
40000
0.00
A
2023-06-30
Common Shares
40000
40000
D
Option to Purchase Common Shares
3.15
2022-06-30
Common Shares
20000
20000
D
Option to Purchase Common Shares
2.72
2021-06-30
Common Shares
20000
20000
D
Option to Purchase Common Shares
3.57
2020-06-30
Common Shares
20000
20000
D
Option to Purchase Common Shares
3.29
2019-10-03
Common Shares
20000
20000
D
Will become exercisable on June 30, 2019, based upon continued service on the board of directors.
Became exercisable in four equal quarterly installments after the date of grant on July 1, 2017.
Became exercisable in four equal quarterly installments after the date of grant on July 1, 2016.
Became exercisable in four equal quarterly installments after the date of grant on July 1, 2015.
Became exercisable in four equal quarterly installments after the date of grant on October 4, 2014.
/s/Michael H. Mulroy
2018-07-03